EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BICO Group (CLLKF) fair value: what the stock is really worth

We calculate from audited financials what BICO Group is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN SE0013647385

BG BICO Group logo Thin data Sep 13, 2026

BICO Group

CLLKF · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $3.00 · Undervalued (+33%)
!Quality 49/100
!Weak Growth (revenue 5y +53.2 %/yr)
!Loss-making · -66.1% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
Watch BICO Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$65.00 $1.52 Fair Value $3.00 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $1.52 – $65.00 · fair‑value band $2.65 – $3.56 · the $2.26 price screens below the $3.00 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation.

Show more

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Stock analysis

BICO Group (CLLKF) currently trades at $2.26, while our model-based Fair Value estimate is $3.00, implying the stock looks roughly 24.7% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $28.86 per share, and 7 of the 7 models we run sit above the $2.26 price.

Bear case: the Asset-Based group reads lowest at $16.92, and 0 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: $2.65 (bear) to $3.56 (bull), the price of $2.26 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

BICO Group reported revenue of 1.5B SEK in FY2025 versus 1.3B SEK in FY2021, a compound +4.4%/yr. Reported net income was −1.1B SEK in FY2025.

Key figures

Market cap $159M · P/S ratio 0.07 · EPS (TTM) $−2.23 · Net margin −72.7% · Return on equity −69.3% · Return on assets (EBIT) −5.6% · Revenue (TTM) $1.8B · Revenue growth (YoY) −1.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The share trades about 43% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at 33%, CLLKF screens cheaper than that median.

Fair Value models

Bear $2.65 Fair Value $3.00 Bull $3.56
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $27.94 $31.73 $42.79 77
Growth DCF $27.35 $32.78 $41.26 76
5Y Revenue Exit $26.87 $32.55 $44.41 70
All 7 models by family
DCF Models
FCF DCF $27.94 $31.73 $42.79 77
5Y Revenue Exit $26.87 $32.55 $44.41 70
10Y Revenue Exit $27.01 $35.84 $41.13 64
Multiples
EV/Revenue $25.75 $28.86 $31.96 54
Asset-Based
NCAV (Graham) $12.63 $16.92 $25.25 54
Growth DCF
Growth DCF $27.35 $32.78 $41.26 76
Rev-Margin DCF $27.72 $34.57 $48.92 69

Open the full fair value analysis →

Notify me when CLLKF reaches fair value

Put CLLKF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 18

Profitability 10
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 44
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 73
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−23.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.2%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+83.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.4% (2020) → −16.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.4%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+4.9%
Forecast 2027 (sales)+7.8%
Projected 2028 (sales)+7.1%
Projected 2029 (sales)+6.4%
Projected 2030 (sales)+5.6%

Watch CLLKF, get fair value alerts →

Compare BICO Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 356 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +59% · Top 25%
Profitability
Return on assets −4% · Below median
Net margin (TTM) −66% · Bottom 25%
Operating margin (TTM) 0% · Below median
Growth and dividend
Revenue growth −1% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.07× · Cheapest 25%
P/S (TTM) 0.07× · Cheapest 25%
P/FCF 2.3× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.95 $74.79 −27%
Stryker Corporation SYK $275.56 $303.12 +10%
Medtronic plc MDT $90.96 $65.57 −28%
Boston Scientific Corporation BSX $42.98 $47.28 +10%
Edwards Lifesciences Corporation EW $84.37 $82.04 −3%
Siemens Healthineers AG SHL €38.23 €33.87 −11%
DexCom, Inc DXCM $83.03 $91.33 +10%
GE HealthCare Technologies Inc GEHC $63.93 $64.13 +0%
Koninklijke Philips N.V PHIA €21.14 €14.36 −32%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥162.73 ¥179.00 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BICO Group · Fair Value
$3.00 +25%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BICO Group Fair Value". https://www.fairvalue-calculator.com/stock/CLLKF

Frequently asked questions

Is BICO Group (CLLKF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $3.00 versus a price of $2.26, about +33% upside (undervalued).
What is the fair value of CLLKF?
Our model-based fair value for BICO Group is $3.00 (as of Sep 13, 2026), built from audited fundamentals. The current price: $2.26.
What is the quality score of CLLKF?
BICO Group has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BICO Group (CLLKF)?
Our model-based price target is the fair value of $3.00 (as of Sep 13, 2026) from 7 valuation models. Cautious scenario $2.65, optimistic scenario $3.56. It is a calculation from audited fundamentals, not an analyst target.
What is the BICO Group stock forecast for 2026?
Our models put fair value at $3.00, about +33% upside versus a price of $2.26 (undervalued). Cautious scenario $2.65, optimistic scenario $3.56. The calculation is refreshed regularly with new filings.
What is the revenue of BICO Group (CLLKF)?
BICO Group reported trailing-twelve-month revenue of about $1.8B (latest available figure, as of Sep 13, 2026).
What growth is priced into BICO Group (CLLKF)?
For today's price to be fair in a discounted-cash-flow model, BICO Group would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 15.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +53.2 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of CLLKF use?
Our models discount BICO Group at 15.2 %: a base by market capitalisation (micro), damped by beta 2.55, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BICO Group that is less than minus 40 % per year a year over ten years, using the same discount rate (15.2 %) and the same formula as our fair value.
How much growth has BICO Group (CLLKF) delivered so far?
Over the past 5 years revenue at BICO Group grew +53.2 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BICO Group (CLLKF) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into BICO Group (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BICO Group (CLLKF)?
The free-cash-flow yield on the price is 34.48 %: that much free cash flow BICO Group produces per unit of market value. When it exceeds the discount rate of our models (15.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BICO Group (CLLKF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BICO Group it is $3.00 per share (as of Sep 13, 2026), against a price of $2.26. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is BICO Group stock overvalued or undervalued in 2026?
As of Sep 13, 2026, CLLKF trades below its calculated fair value: price $2.26, fair value $3.00, a gap of about +33% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLLKF?
No. The price is what the market pays today ($2.26); the fair value is what the company's own numbers justify ($3.00). For BICO Group the two are $0.7415 per share apart. That gap is exactly why we show both numbers side by side.
How much is BICO Group worth?
The market values BICO Group at about $159M (market capitalisation, as of Sep 13, 2026). Per share that is $2.26; our models calculate a fair value of $3.00 per share.
What do the bullish and bearish scenarios say about CLLKF?
Our models span a range for BICO Group: cautious scenario $2.65, base $3.00, optimistic $3.56 per share (as of Sep 13, 2026, price $2.26). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BICO Group (CLLKF)?
Balance-sheet figures for BICO Group (as of Sep 13, 2026): return on equity −69.3%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is CLLKF from its 52-week high?
BICO Group trades at $2.26, about 43% below its 52-week high of $3.95 and 28% above the low of $1.76 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $3.00 is for.
Which stocks are comparable to BICO Group?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BICO Group stock attractive at the current price?
The data as of Sep 13, 2026: price $2.26, calculated fair value $3.00 (+33%), Quality Score 49/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLLKF calculated?
We run BICO Group through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. BICO Group currently trades 33 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with BICO Group right now?
The price is below even our cautious bear case ($2.65). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of BICO Group

How large is the market capitalisation of BICO Group (CLLKF)?
The market capitalisation of BICO Group is $159M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BICO Group (CLLKF)?
The price-to-sales ratio of BICO Group is 0.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BICO Group (CLLKF)?
Earnings per share at BICO Group are $−2.23. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BICO Group (CLLKF)?
The net margin of BICO Group is −72.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BICO Group (CLLKF)?
The return on equity (ROE) of BICO Group is −69.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BICO Group (CLLKF)?
On an EBIT basis the return on assets of BICO Group is −5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at BICO Group (CLLKF)?
Revenue at BICO Group is growing −1.4% versus a year earlier (3y avg −12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does BICO Group (CLLKF) carry?
The net debt of BICO Group is $222M (fiscal year 2025, ≈ 4.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BICO Group in the live analysis

One click puts BICO Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.